Meeting
2017 Genitourinary Cancers Symposium
Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Tanya B. Dorff
Keck School of Medicine, University of Southern California, Los Angeles, CA
Tanya B. Dorff , David I. Quinn , Jacek K. Pinski , Amir Goldkorn , Sarmad Sadeghi , Denice Tsao-Wei , Susan G. Groshen , Peter Kuhn , Mitchell E. Gross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01685125
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 167)
DOI
10.1200/JCO.2017.35.6_suppl.167
Abstract #
167
Poster Bd #
F21
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients.
First Author: M. Andreas Roeder
Poster
2013 Genitourinary Cancers Symposium
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.
First Author: Daniel Petrylak
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2022 ASCO Genitourinary Cancers Symposium
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett